Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Not Confirmed
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Not Confirmed
Not Confirmed
17-19 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BePharma
Not Confirmed
Contact SupplierBePharma
Industry Trade Show
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Industry Trade Show
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Industry Trade Show
Not Confirmed
17-19 March, 2026
Digital content
NEWS #PharmaBuzz
25 Oct 2024
// BUSINESS STD
https://www.business-standard.com/companies/results/eris-lifesciences-q2fy25-results-profit-skids-25-8-revenue-up-46-6-124102501368_1.html
02 Feb 2024
// PRESS RELEASE
https://www.strides.com/pdf/pressrelease/2024/StridesSEIntimationEris_02Feb2024.pdf
05 May 2022
// EXPRESS PHARMA
https://www.expresspharma.in/eris-enters-dermatology-therapy-acquires-oaknet-healthcare-for-rs-6500-million/
04 Dec 2019
// BUSINESS STANDARD
https://www.business-standard.com/article/companies/eris-lifesciences-acquires-trademark-zomelis-from-novartis-ag-for-13-mn-119120301413_1.html
01 Jul 2019
// PHARMABIZ
05 Mar 2018
// BUSINESS-STANDARD
http://www.business-standard.com/article/markets/eris-lifesciences-trades-higher-for-fifth-straight-trading-days-118030600149_1.html
Drugs in Development
Details:
The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for hypertension and angina pectoris.
Lead Product(s): Metoprolol Succinate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: Biocon
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 13, 2024
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Biocon
Deal Size : $150.0 million
Deal Type : Collaboration
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 mln
Details : The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for hypertension and angina pectoris.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 13, 2024
Details:
Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.
Lead Product(s): Everolimus
Therapeutic Area: Oncology Brand Name: Advacan
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: Biocon
Deal Size: $43.8 million Upfront Cash: Undisclosed
Deal Type: Divestment November 09, 2023
Lead Product(s) : Everolimus
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Biocon
Deal Size : $43.8 million
Deal Type : Divestment
Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations
Details : Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.
Product Name : Advacan
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 09, 2023
Details:
Under the agreement, Dr. Reddy’s divests certain non-core brands including Hydroheal, Gris ODT, Revilus, Revibra, Avarta, Salicylix (salicylic acid), Clearz, Acrofy and Aquaderm, in dermatology in India to Eris Lifesciences.
Lead Product(s): Salicylic Acid
Therapeutic Area: Dermatology Brand Name: Salicylix
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: Dr. Reddy\'s Laboratories
Deal Size: $33.2 million Upfront Cash: Undisclosed
Deal Type: Divestment March 16, 2023
Lead Product(s) : Salicylic Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Dr. Reddy\'s Laboratories
Deal Size : $33.2 million
Deal Type : Divestment
Dr. Reddy’s Divests Certain Non-Core Brands in Dermatology in India to Eris Lifesciences to Focu...
Details : Under the agreement, Dr. Reddy’s divests certain non-core brands including Hydroheal, Gris ODT, Revilus, Revibra, Avarta, Salicylix (salicylic acid), Clearz, Acrofy and Aquaderm, in dermatology in India to Eris Lifesciences.
Product Name : Salicylix
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 16, 2023
Details:
Onabet Cream (sertaconzole nitrate) is an antifungal medicine used to treat fungal infections of the skin. It works by killing the fungus that causes infections such as athlete's foot, Dhobie Itch, thrush, ringworm, and dry, flaky skin.
Lead Product(s): Sertaconzole Nitrate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Onabet
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: Glenmark Pharmaceuticals
Deal Size: $41.6 million Upfront Cash: Undisclosed
Deal Type: Divestment January 17, 2023
Lead Product(s) : Sertaconzole Nitrate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Glenmark Pharmaceuticals
Deal Size : $41.6 million
Deal Type : Divestment
Eris Lifesciences To Buy Some Dermatology Brands From Glenmark Pharma
Details : Onabet Cream (sertaconzole nitrate) is an antifungal medicine used to treat fungal infections of the skin. It works by killing the fungus that causes infections such as athlete's foot, Dhobie Itch, thrush, ringworm, and dry, flaky skin.
Product Name : Onabet
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
